AMSBIO has launched a new 2024 travel grant award scheme for scientists under the age of thirty, employed in academia, research institutions, or companies engaged in cancer and stem cell research.
Working closely with the global life science community for over three decades AMSBIO believes in partnership and paying back by supporting new research and researchers. Last year, the company funded a travel grant to attend ISSCR 2023. It was so popular that this year AMSBIO are offering two grant schemes: one for the AACR Annual Meeting 2024 in San Diego, USA, and another for the ISSCR Annual Meeting 2024 in Hamburg, Germany.
On offer are two $1,000 grants for young science professionals to help with their flights, accommodation, entry ticket, food, or anything else they might need while attending AACR 2024 (7-170th April), or ISSCR 2024 (11-13th July).
Marketing Manager, Krystyna Joyce, comments “We are so pleased to be able to offer not only one but two Travel Grants to up-and-coming researchers. We know that attending conferences allows scientists to meet leading experts, network with fellow researchers, and learn about new and innovative research, accelerating their career and scientific progress.”
To be considered for the 2024 travel grant schemes please visit https://www.amsbio.com/news/isscr2023-1000-dollar-travel-grant-2/ and provide a summary of up to 3000 characters describing your current stem cell-related research. Alternatively, if you are presenting a poster at either meeting you can submit your abstract instead.
AMSBIO strives to help advance stem cell discovery by supplying research scientists with the necessary tools and reagents needed to work more efficiently and obtain reliable results faster. Stem cells, particularly human embryonic stem cells, are a notoriously labile cell type. Without careful attention, these cells tend to spontaneously differentiate and undergo genomic rearrangements in culture. Today, AMSBIO offers researchers an unmatched range of high-performance stem-cell-optimized and qualified growth media, sera, feeder cells, supplements, growth factors and assay kits.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.
AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
North American HQ
Dr Bill Bradbury email@example.com